Bioxyne has signalled that revenue growth will return in the fourth quarter of the financial year, following an 11% decline in Q3.
The company attributed the fall to several factors, among them the commissioning of new equipment at its Brisbane facility and the seasonal summer slowdown.
Bioxyne, which operates under the name Breathe Life Sciences (BLS), said it remains on track to meet its previously stated full-year revenue guidance of A$25 million. The company's nine-month revenue total — including the $7.2m recorded in Q3 — stands at $19.7m, a 213% increase on the equivalent period in FY24.
Chief executive Sam Watson said: "We maintain our course of sustainable, profitable growth with another solid quarter. Q3 is typically the slowest period of the year with the new year and summer holiday [and] as a business we always expect a dip in January.
"Nonetheless, customer cash receipts were up 14% from Q2 and revenue has increased 352% from Q3 FY24."
He added: "The commissioning of our new, state-of-the-art, $50m-a-year pastille manufacturing facility and installation of our new vault will allow us to continue delivering even stronger results going forward."
Bioxyne posted positive cash flows of $1.9m over the three months to March, continuing a run that included $1.2m and $1.7m in the two preceding quarters.
During the quarter, the company raised $3m in part to support European expansion, and also extended a manufacturing agreement with Nectartek Australia.
The company held available cash of $6.5m as of March 31.
